Navigation Links
Kendle Announces First Quarter 2009 Results
Date:5/6/2009

57,977 59,170 Reimbursable out-of-pocket costs 36,958 44,689 Selling, general and administrative expenses 38,030 37,624 Depreciation and amortization 3,958 3,355 Total costs and expenses 136,923 144,838 Income from operations 8,138 13,975 Other income (expense): Interest expense (3,876) (4,437) Interest income 230 252 Other 3,163 (2,608) Total other (expense) (483) (6,793) Income before income taxes 7,655 7,182 Income taxes 6,769 3,078 Net income $886 $4,104 Income per share data: Basic: Net income per share $0.06 $0.28 Weighted average shares outstanding 14,842 14,690 Diluted: Net income per share $0.06 $0.27 Weighted average shares outstanding 14,975 14,975 Reconciliation of proforma net income: Net income $886 $4,104 Additional interest expense due to adoption of APB 14-1 1,672 1,520 Discrete tax item related to foreign currency hedge 4,441 - Proforma net income (2) $6,999 $5,624 Proforma net income per share (2) Basic $0.47 $0.38 Diluted $0.47 $0.38
'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... LAKE CITY, Feb. 29 DW Healthcare ... announced today the sale of one,of its ... Laboratory,Corporation of America(R) Holdings (LabCorp(R)), one of ... Salt Lake City, UT, Tandem,Labs is a ...
... Feb. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... the Company,s Senior Vice President, Administrative & ... accepted the position of,Vice President and Chief ...
... On Friday, February 29, the Johnson & Johnson ... the U.S., designed to improve how,practitioners deliver diabetes care ... be devoted to training community health,professionals., Diabetes affects ... billion a year -- about as much as the ...
Cached Biology Technology:AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care 2
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... N.Y. A billion people living in underdeveloped areas ... that survive by residing in and feeding on their ... systemic) illnesses leading to long-term disability. Irah King and ... investigating illnesses caused by these gut-dwelling worms in an ...
... Mo. Americans spend $25 billion a year on ... While the Nutrition Business Journal forecasts that sales of ... over the next five years, scientists still don,t know ... harmful to humans. Now, with a new $7.5 million ...
... Max Planck Institute for Chemical Ecology in Jena, Germany, ... pending for 40 million years. Arum palaestinum ... flies) as pollinators by emitting odor molecules that resemble ... by yeast. The plant accomplishes the illusion of yeast ...
Cached Biology News:Studying illnesses caused by worms: Scientists are learning how immune cells communicate 2MU establishes National Botanical Research Center 2Deceitful lily fools flies 2Deceitful lily fools flies 3
... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
Biology Products: